Grisham, Rachel; Monk, Bradley J.; Van Nieuwenhuysen, Els; 85533; Moore, Kathleen Nadine; Fabbro, Michel; O'Malley, David M.; Oaknin, Ana; Thaker, Premal; Oza, Amit M.; Colombo, Nicoletta;
...
BACKGROUND: There are no approved treatments specifically for low grade serous ovarian cancer; current standard of care treatment options are limited in efficacy and tolerability. The combination of avutometinib with defactinib has demonstrated efficacy and a consistent safety profile in two clinical trials in recurrent low grade serous ovarian can...
Yeh, Christine Yiwen Aguirre, Karmen Laveroni, Olivia Kim, Subin Wang, Aihui Liang, Brooke Zhang, Xiaoming Han, Lucy M Valbuena, Raeline Bassik, Michael C
...
The drivers of immune evasion are not entirely clear, limiting the success of cancer immunotherapies. Here we applied single-cell spatial and perturbational transcriptomics to delineate immune evasion in high-grade serous tubo-ovarian cancer. To this end, we first mapped the spatial organization of high-grade serous tubo-ovarian cancer by profiling...
Kwong, Fong Lien Audrey; Kristunas, Caroline; Davenport, Clare; Deeks, Jon; Mallett, Sue; Agarwal, Ridhi; Kehoe, Sean; Timmerman, Dirk; 17301; Bourne, Tom; Stobart, Hilary;
...
OBJECTIVE: Symptom-triggered testing for ovarian cancer was introduced to the UK whereby symptomatic women undergo an ultrasound scan and serum CA125, and are referred to hospital within 2 weeks if these are abnormal. The potential value of symptom-triggered testing in the detection of early-stage disease or low tumor burden remains unclear in wome...
Meagher, Nicola S White, Kami K Wilkens, Lynne R Bandera, Elisa V Berchuck, Andrew Carney, Michael E Cramer, Daniel W Cushing-Haugen, Kara L Jordan, Susan Kaufmann, Scott H
...
Limited estimates exist on risk factors for epithelial ovarian cancer (EOC) in Asian, Hispanic, and Native Hawaiian/Pacific Islander women. Participants in this study included 1734 Asian (n = 785 case and 949 control participants), 266 Native Hawaiian/Pacific Islander (n = 99 case and 167 control participants), 1149 Hispanic (n = 505 case and 644 c...
Saner, Flurina AM Takahashi, Kazuaki Budden, Timothy Pandey, Ahwan Ariyaratne, Dinuka Zwimpfer, Tibor A Meagher, Nicola S Fereday, Sian Twomey, Laura Pishas, Kathleen I
...
PurposeThe purpose of this study was to evaluate RB1 expression and survival across ovarian carcinoma histotypes and how co-occurrence of BRCA1 or BRCA2 (BRCA) alterations and RB1 loss influences survival in tubo-ovarian high-grade serous carcinoma (HGSC).Experimental designRB1 protein expression was classified by immunohistochemistry in ovarian ca...
Parsons, Michael T de la Hoya, Miguel Richardson, Marcy E Tudini, Emma Anderson, Michael Berkofsky-Fessler, Windy Caputo, Sandrine M Chan, Raymond C Cline, Melissa S Feng, Bing-Jian
...
The ENIGMA research consortium develops and applies methods to determine clinical significance of variants in hereditary breast and ovarian cancer genes. An ENIGMA BRCA1/2 classification sub-group, formed in 2015 as a ClinGen external expert panel, evolved into a ClinGen internal Variant Curation Expert Panel (VCEP) to align with Food and Drug Admi...
Coleman, Robert L.; Lorusso, Domenica; Oaknin, Ana; Cecere, Sabrina Chiara; Denys, Hannelore; Colombo, Nicoletta; van Gorp, Toon; 43578; Konner, Jason A.; Marin, Margarita Romeo; Harter, Philipp;
...
OBJECTIVE: The single-arm, phase II SORAYA trial (NCT04296890) of mirvetuximab soravtansine-gynx in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer (n=105 (efficacy-evaluable)) met its primary endpoint with an objective response rate of 32.4% (95% CI, 23.6 to 42.2). Here we report final SORAYA trial results for overall survival a...
Foslund, Ingrid Terese von Magius, Sahra Aisha Vinholt Ainsworth, Alan Patrick Detlefsen, Sönke Fristrup, Claus Wilki Knudsen, Anja Oer Mortensen, Michael Bau Tarpgaard, Line Schmidt Jochumsen, Kirsten Marie Graversen, Martin
...
Published in
Pleura and Peritoneum
Objectives There are few data on Pressurized IntraPeritoneal Aerosol Chemotherapy with cisplatin and doxorubicin (PIPAC C/D) in women with primary unresectable or recurrent platinum-resistant peritoneal metastasis (PM) from ovarian cancer (OC). We evaluated survival, histological and cytological response, Quality of Life (QoL) and toxicity after PI...
Gaillard, Duco H.K.; Lof, Pien; Sistermans, Erik A.; Mokveld, Tom; Horlings, Hugo Mark; Mom, Constantijne H.; Reinders, Marcel J.T.; Amant, Frederic; 43256; van den Broek, Daan; Wessels, Lodewyk F.A.;
...
OBJECTIVE: To assess the feasibility of scalable, objective, and minimally invasive liquid biopsy-derived biomarkers such as cell-free DNA copy number profiles, human epididymis protein 4 (HE4), and cancer antigen 125 (CA125) for pre-operative risk assessment of early-stage ovarian cancer in a clinically representative and diagnostically challengin...
Xu, Alexander M Haro, Marcela Walts, Ann E Hu, Ye John, Joshi Karlan, Beth Y Merchant, Akil Orsulic, Sandra
High-grade serous ovarian carcinoma (HGSOC), the deadliest form of ovarian cancer, is typically diagnosed after it has metastasized and often relapses after standard-of-care platinum-based chemotherapy, likely due to advanced tumor stage, heterogeneity, and immune evasion and tumor-promoting signaling from the tumor microenvironment. To understand ...